In-market Utilisation of Liraglutide Used for Weight Management in Europe

Sponsor
Novo Nordisk A/S
Study ID
NCT02967757
Status
Completed

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients

Study Details

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Key Dates

Start date
Dec 22, 2016
Status verified
Jan 2023
Primary completion
May 28, 2019
Completion
May 28, 2019

Study Design

Enrollment
316 participants (actual)

Arms

  • Arm: liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg

Primary Outcome Measure

Number of patients with BMI above or equal to 30 kg/m^2 [ Time Frame: Less than 6 months before date of first prescription ]

Related Studies